Regeneron’s Eylea Patent Upheld as Biocon’s Challenge Fails Due to Timing Error
In a recent decision by the U.S. Patent and Trademark Office, Director John Squires rejected Biocon Biologics’ challenge to a patent held by Regeneron Pharmaceuticals on their eye disorder treatment, Eylea. The main reason for dismissing the challenge was that Biocon’s petition was submitted beyond the allowable timeframe for contesting the patent. This outcome highlights…